Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, ...
Neonates were monitored with a cerebral oximeter before, during, and after cannulation for ECMO to determine the direct effects of ligation of the right internal jugular vein and right carotid artery ...
To describe the use of double-lumen venovenous (VVDL) extracorporeal membrane oxygenation (ECMO) with cephalic draining cannula (VVDL+V) as a primary approach for all neonatal respiratory diagnoses ...
You may think of ventilators as the last line of defense for patients who are critically ill with COVID-19. But that’s not always the case. Next-level life support exists for some of the sickest ...
Extracorporeal membrane oxygenation (ECMO) is a method of providing lung and heart support to patients with inadequate blood perfusion in the body, or gas exchange in the lungs. Blood is pumped from ...
Registry data reaffirmed extracorporeal membrane oxygenation (ECMO) as a reasonable strategy for COVID-19 patients with severe respiratory problems, with most survivors discharged home and several ...
ECMO stands for extracorporeal membrane oxygenation. An ECMO machine takes blood from your veins, pumps it outside the body (extracorporeal), removes carbon dioxide, adds oxygen (oxygenation), and ...
A recently published study by FMI expects the global Arterial Cannula Market to augment at a 6.6% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 40 Billion is ...
The global arterial cannula market has witnessed remarkable growth, reaching a market value of USD 21 billion in 2023. With a robust compound annual growth rate (CAGR) of 6.6%, this market is ...
Please provide your email address to receive an email when new articles are posted on . After the intervention, BSIs in patients with ECMO decreased from a high of 36% in October 2021 to 0% in June ...
LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned ...
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days' use LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback